Evidence map›Paper›PMID 32773396›Full record

ArticleJournal of Parkinson's disease2020

Does Serum Urate Change as Parkinson's Disease Progresses?

Yasemin G Hasimoglu, Xiqun Chen, Rachit Bakshi, Michael A Schwarzschild, Eric A Macklin

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yasemin G HasimogluDepartment of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.
Xiqun ChenDepartment of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.
Rachit BakshiDepartment of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.
Michael A SchwarzschildDepartment of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.
Eric A MacklinDepartment of Medicine, Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital · US

Funding

Phase 3 trial of inosine for Parkinson's disease CCCU01NS090259 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHWARZSCHILD, MICHAEL A · 2015 to 2019
$16.9M
Urate-LRRK2 interactions in Parkinson's diseaseR01NS110879 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHWARZSCHILD, MICHAEL A · 2019 to 2023
$2.0M
MC1R Basis of Melanoma-Parkinson's Link and Neuroprotective Potential of MC1RR01NS102735 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2018 to 2022
$1.8M
Neuroprotection by MC1R as the basis for the melanoma-Parkinson's disease linkR21NS090246 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2015 to 2016
$450k
NINDS NIH HHS R01 NS102735NINDS NIH HHS R01 NS110879NINDS NIH HHS R21 NS090246NINDS NIH HHS U01 NS090259
6 · The paper itself

Abstract

Higher serum urate concentration is associated with decreased risk of Parkinson's disease (PD) as well as slower disease progression, but its relationship with severity of PD remains unclear. This study investigated whether changes in serum urate concentration over 5 years were associated with disease progression assessed by MDS-UPDRS Part III score, Hoehn and Yahr stage, or DaTscan imaging. Average serum urate concentration was stable over time and change in serum urate concentration did not correlate with worsening of measures of PD progression. These results suggest that serum urate concentration is not a monitoring biomarker of PD progression in early stages.

Indexed as

Disease ProgressionAgedBiomarkersCorpus StriatumDopamine Plasma Membrane Transport ProteinsFemaleHumansLongitudinal StudiesMaleMiddle AgedParkinson DiseaseSeverity of Illness IndexUric AcidBiomarkersDopamine Plasma Membrane Transport ProteinsUric Aciddisease progressionlongitudinal studyParkinson’s diseaseurate

Identifiers

PMID32773396
PMCPMC7683051
OpenAlexW3047073005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.